<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:10:03Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/16816" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/16816</identifier><datestamp>2026-10-18T20:38:55Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>The Role of Endothelin and Prostacyclin on Recombinant Erythropoietin-a Induced Hypertension in Hemodialysis Patients</dc:title><dc:creator>Turkmen, Kultigin</dc:creator><dc:creator>Erdur, Fatih Mehmet</dc:creator><dc:creator>Dalmaz, Mahmut</dc:creator><dc:creator>Yeksan, Mehdi</dc:creator><dc:creator>Akkus, Idris</dc:creator><dc:creator>Turk, Suleyman</dc:creator><dc:subject>Hemodialysis</dc:subject><dc:subject>Erythropoietin</dc:subject><dc:subject>Endothelin</dc:subject><dc:subject>Prostacyclin</dc:subject><dc:subject>Hypertension</dc:subject><dc:subject>Urology &amp; Nephrology</dc:subject><dc:description>OBJECTIVE: Recombinant human erythropoietin (r-HuEPO) was found to be associated with increased blood pressure in hemodialysis (HD) patients. Plasma endothelin-1(ET-1) was reported to be increased during treatment with r-huEPO in HD patients. Prostacyclin (PGI2) was found to be associated with the reduction in vascular resistance. We aimed to determine the role of ET-1 and PGI2 on r-huEPO-induced hypertension in HD patients. MATERIAL and METHODS: 43 HD patients (19 females, 24 males) were randomly assigned to groups. Group 1 (n= 15) consisted of patients receiving r-HuEPO-a subcutaneously after each dialysis session for 6 to 42 months. Group 2 (n= 15, control group) consisted of patients who did not receive any r-huEPO and group 3 (n= 13) consisted of patients who received r-huEPO-a subcutaneously after each dialysis session for 12 weeks. Plasma ET-1,2 and 6-keto-PGF1-a were measured. RESULTS : There were no differences in terms of ET-1,2 and 6-keto-PGF1-a, systolic and diastolic BP and hematocrit levels in group 1 and group 2 patients. However, in group 3 patients, hematocrit, plasma ET1,2 and 6-keto PGF1-a levels were significantly elevated after 12 weeks of rHuEPO treatment. CONCLUSION: We showed that ET-1.2 and 6-keto-PGF1-a levels were found to be significantly increased with 12 weeks of rHu-EPO therapy in HD patients.</dc:description><dc:publisher>TURK NEFROLOJI DIYALIZ TRANSPLANTASYON DERGISI</dc:publisher><dc:date>2013</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/16816</dc:identifier><dc:identifier>https://doi.org/10.5262/tndt.2013.1001.13</dc:identifier><dc:identifier>1300-7718</dc:identifier><dc:language>en</dc:language><dc:relation>TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/16816</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>